

primary studies - published RCT

# Inhalation Treatment with Glutathione in Patients with Cystic Fibrosis: a Randomized Clinical Trial.

**Code:** PM23631796

**Year:** 2013 **Date:** 2017

**Author:** Griese M

## Study design (if review, criteria of inclusion for studies)

Randomized, double-blind, placebo-controlled, phase 3, crossover trial

## Participants

248 patients 12 years of age or older who had cystic fibrosis and were heterozygous for the Phe508del mutation and a CFTR mutation associated with residual CFTR function.

## Interventions

Patients were randomly assigned to one of six sequences, each involving two 8-week intervention periods separated by an 8-week washout period. They received tezacaftor-ivacaftor, ivacaftor monotherapy, or placebo.

## Outcome measures

The primary end point was the absolute change in the percentage of predicted forced expiratory volume in 1 second (FEV1) from the baseline value to the average of the week 4 and week 8 measurements in each intervention period.

## Main results

The number of analyzed intervention periods was 162 for tezacaftor-ivacaftor, 157 for ivacaftor alone, and 162 for placebo. The least-squares mean difference versus placebo with respect to the absolute change in the percentage of predicted FEV1 was 6.8 percentage points for tezacaftor-ivacaftor and 4.7 percentage points for ivacaftor alone (P

## Authors' conclusions

CFTR modulator therapy with tezacaftor-ivacaftor or ivacaftor alone was efficacious in patients with cystic fibrosis who were heterozygous for the Phe508del deletion and a CFTR residual-function mutation. (Funded by Vertex Pharmaceuticals and others; EXPAND ClinicalTrials.gov number, NCT02392234 .).

<http://dx.doi.org/10.1164/rccm.201303-0427OC>

## See also

Am J Respir Crit Care Med. 2013 Apr 30.

## Keywords

Adult; Aged; CFTR Modulators; Genetic Predisposition to Disease; pharmacological\_intervention; placebo; VX-770; VX-661; ivacaftor; Aminophenols; tezacaftor; Symdeko; Symkevi;